Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

230 results about "Aminocaproic acid" patented technology

This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis).

Composite polymer bone-renovation material containing ceramic component and preparation method thereof

The present invention relates to a bone-repairing composite polymer material containing a ceramic ingredient and a preparation method thereof. The bone-repairing composite polymer material is composed of the calcium phosphate ceramic ingredient and a polybasic amino acid polymer ingredient, wherein, the mass ratio of the calcium phosphate ceramic ingredient is between 5 percent and 30 percent, and the rest is the polybasic amino acid polymer ingredient. Epsilon-aminocaproic acid is polymerized with at least two other types of amine acids to form the polybasic amino acid polymer ingredient, wherein, the mole ratio of the epsilon-aminocaproic acid in the polybasic amino acid polymer ingredient is between 50 percent and 90 percent, and the rest is the other amine acids including aminoacetic acid, lactamic acid, phenylalanine, lysine and proline. Under the protection of a inert gas, the materials, the amine acids and the calcium phosphate, are sufficiently and uniformly dispersed into water and then heated, so that various forms of waters can be removed from the materials, and finally, the materials are polymerized in two steps, respectively under a temperature between 200 DEG C and 220 DEG C and a temperature between 230 DEG C and 250 DEG C. The bone-repairing composite polymer material, which has excellent mechanical property, bioactivity, biocompatibility and controllable degradation property, can be perfectly combined with the interface of the bone tissue, and moreover, the degradation product is non-toxic and non-irritant.
Owner:SICHUAN GUONA TECH

Process for the carbonylation of pentenenitrile

Processes to prepare 5-cyanovaleric acid or its ester are provided, by carbonylation of a pentenenitrile, wherein pentenenitrile is reacted with carbon monoxide and water and / or an alcohol in the presence of a catalyst system. The catalyst system contains:(a) a metal of Group VIII or a compound thereof and(b) a bidentate phosphine, arsine and / or stibine ligand, wherein the bidentate ligand has the general formula (I):R1R2-M1-R-M2-R3R4  (I) wherein M1 and M2 are independently P, As or Sb, R is a divalent organic bridging group, which bridging group comprises a chain of 3 to 5 atoms directly connecting the 2 phosphorus atoms, which chain consists of carbon atoms and optionally a nitrogen, oxygen or sulphur atom or a silano or dialkylsilicon group, which alkyl groups independently comprise from 1 to 4 carbon atoms, and R1–R4 represent the same or different optionally substituted tertiary alkyl groups,(c) an acid having a pKa less than 3, as measured at 18° C. in an aqueous solution.ε-caprolactam is also prepared by reduction of 5-cyanovaleric acid or ester obtained above to 6-aminocaproic acid or ester, and then cyclisation of the 6-aminocaproic acid or ester to ε-caprolactam.
Owner:SHELL OIL CO

Stable eye drops containing latanoprost as the active ingredient

The present invention provides a latanoprost ophthalmic solution which can be stored at room temperature and is excellent in stability. The ophthalmic solution according to the present invention is an ophthalmic solution comprising latanoprost, wherein latanoprost is stabilized to be stored at room temperature by at least one means selected from the following 1) and 2); 1) adjusting pH of the solution to 5.0 to 6.25 and 2) adding ε-aminocaproic acid to the solution.
Owner:SANTEN PHARMA CO LTD

Synthesis method of specific salbutamol artificial antigen

The invention discloses a synthesis method of a specific salbutamol artificial antigen, belonging to the technical field of biological chemical engineering. The synthesis method disclosed by the invention comprises the following steps of: activating salbutamol through a formaldehyde solution, and connecting 6-aminocaproic acid in the ortho-position of a phenolic hydroxyl group to obtain a salbutamol hapten; and coupling a carboxyl group on the salbutamol hapten with an amino group on a carrier protein to obtain the salbutamol artificial antigen. The synthesis method disclosed by the invention can make up for the insufficiencies and defects of the existing salbutamol antigen synthesis technologies, the salbutamol artificial antigen with high specificity is obtained, the specificity of a produced antibody is high, and the sensitivity is high; and experimental results show that the antiserum titre of an animal immunized by using the salbutamol artificial antigen disclosed by the invention can achieve 80000, the detection limit is 0.5ng / mL, and the half-inhibitory concentration IC50 is 5ng / mL. The antigen or the antibody disclosed by the invention can be used for establishing an enzyme-linked immunosorbent analytical method and a colloidal gold test strip rapid assay method so as to rapidly detect the residues of the salbutamol in a food and further realize broad application prospects.
Owner:JIANGNAN UNIV

Injection moldable bone repair composite material and preparation method thereof

InactiveCN101716380ARelieve painAppropriate selection rangeProsthesisIn situ polymerizationBiocompatibility Testing
The invention relates to an injection moldable bone repair composite material and a preparation method and a using method thereof. The composite material is a powder material consisting of a copolymer of multiple amino acids and a sulfate component of calcium, the sulfate component of the calcium accounts for 60-95% of total weight of the component material, and the balance is the copolymer of the multiple amino acids. The sulfate component of the calcium comprises alpha-hemihydrated calcium sulfate which accounts for 15%-60% of the total weight of the composite material and the balance of other sulfates of the calcium. The copolymer of the multiple amino acids is formed by polymerizing epsilon-aminocaproic acid and at least two types of other amino acids, and the molar ratio of each amino acid in the other amino acids is not less than 1% of the total weight of the amino acids. When in preparation, an intermediate parent body is obtained by in-situ polymerization and composition of other sulfates of the calcium and the amino acid monomers under inert gas protection and heating, and the composite material is prepared by smashing and then being composed with the alpha-hemihydrated calcium sulfate. The composite material powder is mixed with curing liquid, and then the composite material can be used by injection. The composite material can be fast molded after the injection and has the strength which is equivalent to that of cancellous bone, good biocompatibility and adjustable degradation speed, thereby being applicable to fixation and repair of clinical orthopedic complicated and irregular traumas.
Owner:SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products